ConductScience.org, home

Comparison · NCT00982020-sae

Olanzapine/Standard Behavioral Weight Intervention vs Olanzapine/Intense Behavioral Weight Intervention: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Olanzapine/Standard Behavioral Weight Intervention vs Olanzapine/Intense Behavioral Weight Intervention: serious adverse events. Trial comparisons, record NCT00982020-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00982020-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1270.0760.206wilson
Risk in group 20.1980.1320.286wilson
Risk difference, group 1 minus group 2-0.0706-0.1730.032newcombe hybrid score
Risk ratio, group 1 over group 20.6440.3391.22log
Odds ratio, group 1 over group 20.5920.2771.27log
Number needed to treat, for one fewer participant with a serious adverse event on Olanzapine/Standard Behavioral Weight Intervention than on Olanzapine/Intense Behavioral Weight Intervention14.2from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Olanzapine/Standard Behavioral Weight Intervention
Olanzapine: 2.5mg to 20mg given orally, daily for 52 weeks~Standard behavioral weight intervention: One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only
13102EG000
Group 2Olanzapine/Intense Behavioral Weight Intervention
Olanzapine: 2.5mg to 20mg given orally, daily for 52 weeks~Intense behavioral weight intervention: Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
20101EG001

Harm

What it counts
Total, serious adverse events
Time frame

Source ClinicalTrials.gov

Trial

Title
Study in Adolescents With Schizophrenia or Bipolar Disorder
NCT number
NCT00982020
Phases
PHASE4
Conditions
Bipolar I Disorder, Schizophrenia
Interventions
Olanzapine, Standard behavioral weight intervention, Intense behavioral weight intervention
Lead sponsor
Eli Lilly and Company
Results first posted
2014-12-17

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00982020-sae